Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your breast cancer tests as either HER2-positive or triple-negative (ER negative, PR negative, and HER2 negative), based on local lab tests.
- Your cancer is stage 1, and it must fit specific tumor-size and lymph-node rules (it’s not allowed to be the very smallest pT1aN0 type).
- You can consent before surgery (preferred) or shortly after surgery, and you’re able to complete study visits for blood tests and follow-up for 5 years.
- Your cancer has not spread to distant organs (no distant metastatic disease).
- You have not had chemotherapy or other cancer treatment for this breast cancer before (except surgery if you enroll after surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This Phase 2 study tests whether treatment can be reduced (de-escalated) for people with early-stage (stage I) HER2-positive invasive breast cancer. It aims to keep the cancer under control while potentially reducing treatment intensity and side effects.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.